Metarrestin

Metarrestin (ML246) is an orally active, first-in-class and specific perinucleolar compartment inhibitor. Metarrestin disrupts the nucleolar structure and inhibits RNA polymerase (Pol) I transcription, at least in part by interacting with the translation elongation factor eEF1A2. Metarrestin blocks metastatic development and extends survival in mouse cancer models[1][2].

Product Specifications

CAS Number

[1443414-10-5]

Product Name Alternative

ML246

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/metarrestin.html

Purity

99.90

Solubility

DMSO : 31.25 mg/mL (ultrasonic)

Smiles

O[C@H]1CC[C@H](N(C=NC2=C3C(C4=CC=CC=C4)=C(C5=CC=CC=C5)N2CC6=CC=CC=C6)C3=N)CC1

Molecular Formula

C31H30N4O

Molecular Weight

474.60

Precautions

H315, H319, H320

References & Citations

[1]Vilimas T, et al. Pharmacokinetic evaluation of the perinucleolar compartment disassembler metarrestin in wild-type and Pdx1-Cre; LSL-KrasG12D/+; Tp53R172H/+ (KPC) mice, a genetically engineered model of pancreatic cancer. Cancer Chemother Pharmacol. 2018 Dec;82 (6) :1067-1080.|[2]Frankowski KJ, et al. Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. Sci Transl Med. 2018 May 16;10 (441) .